The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial

Pernille Lassen; Jesper G Eriksen; Annelise Krogdahl; Marianne Hamilton Therkildsen; Benedicte P Ulhøi; Marie Overgaard; Lena Specht; Elo Verner Andersen; Jørgen Johansen; Lisbeth Juhler Andersen; Cai Grau; Jens Overgaard; Danish Head and Neck Cancer Group (DAHANCA)

doi:10.1016/j.radonc.2011.02.010

The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial

Pernille Lassen, Jesper G Eriksen, Annelise Krogdahl, Marianne Hamilton Therkildsen, Benedicte P Ulhøi, Marie Overgaard, Lena Specht, Elo Verner Andersen, Jørgen Johansen, Lisbeth Juhler Andersen, Cai Grau, Jens Overgaard, Danish Head and Neck Cancer Group (DAHANCA)

Research output: Contribution to journal › Journal article › Research › peer-review

159 Citations (Scopus)

Abstract

Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial.

Original language	English
Journal	Radiotherapy & Oncology
Volume	100
Pages (from-to)	49-55
Number of pages	7
ISSN	0167-8140
DOIs	https://doi.org/10.1016/j.radonc.2011.02.010
Publication status	Published - 2011
Externally published	Yes

Bibliographical note

Keywords

Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
Dose Fractionation
Female
Head and Neck Neoplasms
Humans
Male
Middle Aged
Neoplasm Proteins
Papillomaviridae
Proportional Hazards Models

Access to Document

10.1016/j.radonc.2011.02.010

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Lassen, P., Eriksen, J. G., Krogdahl, A., Therkildsen, M. H., Ulhøi, B. P., Overgaard, M., Specht, L., Andersen, E. V., Johansen, J., Andersen, L. J., Grau, C., Overgaard, J., & Danish Head and Neck Cancer Group (DAHANCA) (2011). The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiotherapy & Oncology, 100, 49-55. https://doi.org/10.1016/j.radonc.2011.02.010

@article{4fade54d1c074652b8a239e8980a12a6,

title = "The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial",

abstract = "Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Dose Fractionation, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Proteins, Papillomaviridae, Proportional Hazards Models",

author = "Pernille Lassen and Eriksen, {Jesper G} and Annelise Krogdahl and Therkildsen, {Marianne Hamilton} and Ulh{\o}i, {Benedicte P} and Marie Overgaard and Lena Specht and Andersen, {Elo Verner} and J{\o}rgen Johansen and Andersen, {Lisbeth Juhler} and Cai Grau and Jens Overgaard and {Danish Head and Neck Cancer Group (DAHANCA)}",

year = "2011",

doi = "10.1016/j.radonc.2011.02.010",

language = "English",

volume = "100",

pages = "49--55",

journal = "Radiotherapy & Oncology",

issn = "0167-8140",

publisher = "Elsevier",

}

Lassen, P, Eriksen, JG, Krogdahl, A, Therkildsen, MH, Ulhøi, BP, Overgaard, M, Specht, L, Andersen, EV, Johansen, J, Andersen, LJ, Grau, C, Overgaard, J & Danish Head and Neck Cancer Group (DAHANCA) 2011, 'The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial', Radiotherapy & Oncology, vol. 100, pp. 49-55. https://doi.org/10.1016/j.radonc.2011.02.010

TY - JOUR

T1 - The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial

AU - Lassen, Pernille

AU - Eriksen, Jesper G

AU - Krogdahl, Annelise

AU - Therkildsen, Marianne Hamilton

AU - Ulhøi, Benedicte P

AU - Overgaard, Marie

AU - Specht, Lena

AU - Andersen, Elo Verner

AU - Johansen, Jørgen

AU - Andersen, Lisbeth Juhler

AU - Grau, Cai

AU - Overgaard, Jens

AU - Danish Head and Neck Cancer Group (DAHANCA)

PY - 2011

Y1 - 2011

N2 - Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial.

AB - Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Dose Fractionation

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Proteins

KW - Papillomaviridae

KW - Proportional Hazards Models

U2 - 10.1016/j.radonc.2011.02.010

DO - 10.1016/j.radonc.2011.02.010

M3 - Journal article

SN - 0167-8140

VL - 100

SP - 49

EP - 55

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

ER -

The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Fingerprint

Cite this